Glucoris M1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, contributing to better glycemic control. This dual mechanism addresses both insulin deficiency and insulin resistance, making Glucoris M1 Tablet PR effective in achieving and maintaining target blood glucose levels. The prolonged-release formulation ensures a sustained therapeutic effect, improving patient compliance by reducing dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. It is recommended as an adjunct to diet and exercise when monotherapy with either agent is insufficient for glycemic control. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects is essential during therapy. Glucoris M1 Tablet PR should be used under medical supervision, with dosage adjustments tailored to individual patient response and tolerability to optimize treatment outcomes.